Teva Pharmaceuticals Marc A. Goshko Memorial Grant

Grant at a Glance



From 2009 - 2023, the Teva Pharmaceuticals Marc A. Coshko Memorial grant program supported several academic researchers ("Teva Scholars") in the fields of organic and medicinal chemistry.


The Teva Pharmaceuticals Marc A. Goshko Memorial Grant Program is administered by the ACS Office of Research Grants with funding provided by Teva Pharmaceuticals. The program is named in honor of Marc A. Goshko who was instrumental in initiating it.

  • Years of Program: 2009 - 2023
  • Award Amount: $100,000 per year for 3 years
  • Number of Awards: 1 per cycle
  • Award Period: September 1 to August 31



An applicant must be a recently-tenured faculty member of a Ph.D.-granting department in the United States. Read more about Eligibility, Terms, and Conditions for Teva Pharmaceuticals Marc A. Goshko Memorial Grant Program.


We are not accepting new applications at this time. 

Research Area & Evaluation Criteria

Applications for the Teva Pharmaceuticals Scholars grants must propose research in the area of organic chemistry, with potential or direct connections with medicinal or pharmaceutical chemistry, such that the successful results would be of potential practical benefit to the discovery of organic compounds useful as human medicines. Proposals are evaluated on: a) scientific merit, creativity and novelty; and b) addressing unexplored fields in organic and/or medicinal chemistry. General aspects of research proposals will also be considered, such as: Is the project achievable within the time frame? Are the personnel and facilities adequate? Does the applicant consider and address potential problems?

Budget Guidelines

The following budget restrictions apply:

  • No institutional overhead charges, nor facilities and adminsistrative charges will be charged to the grant nor will any be provided by ACS-Teva.
  • Applications will include a budget in the amount of $100,000 for each of three years (Total = $300,000) with the following categories: personnel (see below); reagents and expendables; permanent equipment; travel. A brief budget explanation should be part of the proposal; budget considerations may be part of the evaluation of the proposal.
  • A maximum of $10,000 per year may be used to support the principal investigator’s salary, including benefits. Postdoctoral fellows, research associates, technicians, graduate students (stipend and/or tuition), and/or undergraduate students may be supported through the grant, at levels commensurate with the grantee’s department or academic unit.
  • A maximum of $5,000 per year may be used for travel, including travel to conferences or symposia, or to collaborating laboratories. Travel to present research results must be budgeted for the third year; (see below).

At the end of each grant year, the grantee will submit a financial report and a scientific progress report; (see below). Of the support given, funds remaining at the end of each grant year may be carried forward into the next year in the same budget category.

Reporting Requirements

Each grant recipient is required to submit annual scientific progress and financial reports to the ACS Office of Research Grants. ACS shall, in its sole discretion and consistent with its standard practices, determine whether the grant recipient is meeting the goals and objectives appropriately.

Each grant recipient is required to present a lecture during or promptly following the grant period at a time and place to be agreed upon by the grant recipient and the ACS. Recipients’ travel costs in connection with the lecture should be budgeted in travel for the third year.

Contact Information

Dr. Nancy Jensen
Program Manager
Phone: 202-872-6186

Marc A. Goshko

Marc Aaron Goshko was born on August 15, 1956 in Philadelphia, PA. He held a BS degree in Biology from Upsala College and an M.S in Microbiology from Drexel University. Marc joined Teva Pharmaceuticals in 1986 in the Regulatory group. During his 27 years with Teva, Marc built the foundations in the US for the Government Affairs, Clinical Trials, Project Management, Biopharmaceuticals, and Intellectual Property groups, as well as managing these functions. He was well-respected among top regulatory attorneys and the FDA, and was regarded as highly knowledgeable in the Hatch-Waxman and the Biologics Price Competition and Innovation Acts. Marc was promoted to Vice President, Product and Patent Strategy as part of Teva’s Legal Group. Surprisingly, Marc had no formal legal training. His zest for life, thirst for knowledge, endless curiosity and keen intellect made him a formidable opponent as well as an amazing teacher. Marc had a true gift for taking the most complex of issues and making it easy for anyone to understand. He took great joy in being able to provide insight into any topic and always made time to help whenever he was asked.

Marc passed away in November 2013, and is survived by his wife Terri, his son Ben, and his daughter-in-law Lisa Dase. His generosity of spirit and self are only a part of Marc’s legacy. For those of us who were lucky enough to have worked with Marc, his knowledge, perspective, advice and sense of humor are truly missed.

During his time at Teva, Marc and his group took on the task of initiating a Teva-supported grant program that would provide research funds to recently tenured university professors whose work was related to organic and medicinal chemistry. Since 2008, six professors have been awarded a total of $1.8 million to pursue research in areas such as natural product synthesis, liposomes, modification of microRNA and synthetic lectins. Today, we are also pleased to announce the three winners of the 2015-2018 Teva Pharmaceuticals Mark A. Goshko Memorial Grant Program. (Boston, August 17, 2015)

Related Opportunities